Study guide
6.1 Respiratory Pharmacology
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
6.1 Respiratory Pharmacology
Key Takeaways Explain This Topic AI
Short-acting beta-2 agonists such as salbutamol cause dose-related tremor, tachycardia and hypokalemia; falling potassium matters most with high-dose nebulised therapy
Long-acting beta-2 agonists must never be used as monotherapy in asthma because masking bronchospasm without anti-inflammatory cover increases asthma mortality - they are always paired with an inhaled corticosteroid
Patients using inhaled corticosteroids should rinse the mouth and spit after each dose to prevent oral candidiasis and dysphonia
Tiotropium and other antimuscarinics require caution in narrow-angle glaucoma and urinary retention from prostatic hypertrophy
Theophylline has a narrow therapeutic index (target 10-20 mg/L) and its level rises with CYP1A2 inhibitors such as ciprofloxacin and falls in smokers
Last updated: August 2026
Asthma and COPD: the Pharmacological Backbone
Respiratory pharmacology is examined heavily within Clinical Pharmacology & Therapeutic Decision Making, the largest content area (20%) of the DHA pharmacist assessment. The exam expects you to know mechanisms, class-specific adverse effects and the counselling points a Dubai community or hospital pharmacist actually gives at the counter.
Beta-2 Agonists
Short-acting beta-2 agonists (SABAs) - salbutamol (albuterol) and terbutaline - relax bronchial smooth muscle by stimulating beta-2 adrenoceptors, raising cyclic adenosine monophosphate. Onset by inhalation is within minutes, making them the reliever of choice for acute symptoms. Adverse effects are extensions of beta stimulation: tremor (skeletal muscle beta-2), tachycardia and palpitations , and hypokalemia from beta-2-mediated shift of potassium into cells - clinically relevant with repeated high-dose nebulised salbutamol in acute asthma.
Long-acting beta-2 agonists (LABAs) - salmeterol (slow onset) and formoterol (fast onset) - provide 12-hour bronchodilation. The critical exam rule: LABAs are never used as monotherapy in asthma . LABA-only treatment masks bronchospasm while airway inflammation progresses, and safety trials showed increased asthma-related deaths. In asthma a LABA is always co-prescribed with an inhaled corticosteroid, usually in a fixed ICS/LABA combination inhaler (budesonide/formoterol, fluticasone/salmeterol). In COPD, LABA monotherapy is acceptable. Non-selective beta-blockers (for example propranolol) antagonise these drugs and can provoke bronchospasm - a classic pharmacist-intervention scenario.
Inhaled Corticosteroids
Inhaled corticosteroids (ICS) - beclometasone, budesonide, fluticasone - are the foundation of persistent asthma control, suppressing airway inflammation. They are preventers, not relievers, and must be taken regularly. Because deposition is oropharyngeal as well as pulmonary, the signature local adverse effects are oral candidiasis (thrush) and dysphonia (hoarse voice) . Counselling: rinse the mouth with water and spit after every dose , and use a spacer with a metered-dose inhaler to cut oral deposition. High-dose ICS over years can cause systemic effects (adrenal suppression, reduced bone density), but at usual doses systemic absorption is minimal.
Antimuscarinics
Long-acting muscarinic antagonists (LAMAs) - tiotropium (once daily) - block M3 receptors, preventing acetylcholine-mediated bronchoconstriction. They are first-line maintenance therapy in COPD and an add-on option in asthma. Adverse effects are anticholinergic: dry mouth , constipation, urinary retention (caution in benign prostatic hyperplasia) and risk of precipitating narrow-angle glaucoma , especially if nebulised drug contacts the eye. Ipratropium is the short-acting counterpart used in acute exacerbations.
Leukotriene Receptor Antagonists
Montelukast blocks cysteinyl leukotriene receptors, useful as add-on therapy in asthma, exercise-induced bronchoconstriction and allergic rhinitis. It is taken orally once daily - a compliance advantage - but carries a regulatory warning for neuropsychiatric effects including agitation, sleep disturbance, depression and suicidal ideation; advise patients and parents to report mood or behaviour changes.
Theophylline
Theophylline , a methylxanthine (phosphodiesterase inhibitor and adenosine receptor antagonist), is now a reserve agent because of its narrow therapeutic index - target plasma concentration 10-20 mg/L . Toxicity begins with nausea and tremor and progresses to cardiac arrhythmias and seizures . It is metabolised by CYP1A2, so levels are increased by inhibitors such as ciprofloxacin, erythromycin and cimetidine, and decreased by inducers including tobacco smoke, carbamazepine and rifampicin. Dose-check whenever interacting drugs start or stop, and when a patient quits smoking.
Biologics and Oxygen
Omalizumab , a monoclonal antibody against immunoglobulin E, represents the biologic class for severe allergic asthma with elevated IgE despite optimised inhaler therapy; it is given by subcutaneous injection and carries an anaphylaxis risk, so doses are administered under observation. In COPD exacerbations use controlled oxygen therapy (24-28% via Venturi mask) targeting SpO2 88-92% : a minority of chronic hypercapnic patients depend on hypoxic drive, and uncontrolled high-flow oxygen can cause dangerous CO2 retention and respiratory acidosis.
Inhaler Technique and Spacer Counselling
Poor technique is the commonest reason inhaled therapy fails. Key counselling points:
Metered-dose inhaler (MDI): shake, exhale fully, seal lips, start a slow deep inhalation and fire the canister simultaneously, then hold the breath ~10 seconds . Coordination problems are solved with a spacer , which also improves lung deposition and reduces thrush with ICS; wash spacers in detergent and air-dry to limit static.
Dry-powder inhaler (DPI): requires a forceful, deep inhalation - unsuitable for patients with very poor inspiratory flow; do not exhale into the device.
Check technique at every refill; rinse-and-spit after ICS-containing inhalers.
Antihistamines and Decongestants
First-generation H1 antihistamines (chlorphenamine, promethazine, diphenhydramine) cross the blood-brain barrier, causing sedation and marked anticholinergic effects (dry mouth, urinary retention, blurred vision) - avoid in the elderly and warn about driving. Second-generation agents (cetirizine, loratadine, fexofenadine) are minimally sedating and preferred for allergic rhinitis and urticaria. For nasal congestion, topical oxymetazoline works rapidly but use beyond about 5-7 days causes rebound congestion (rhinitis medicamentosa) - a favourite exam point. Oral pseudoephedrine is an alternative but is cautioned in hypertension, ischaemic heart disease and hyperthyroidism.
Stepwise Management and Acute Exacerbations
Asthma follows a stepwise approach: low-dose ICS is the preferred controller from the earliest persistent stage, with the ICS dose stepped up or a LABA added when control is poor - always checking adherence and inhaler technique first. Heavy SABA use (more than one reliever canister a month) is a red flag for uncontrolled asthma and increased exacerbation risk, and many guidelines now prefer as-needed low-dose ICS/formoterol over SABA-only reliever therapy. In an acute severe asthma attack , give repeated inhaled or nebulised salbutamol (ipratropium is added in severe episodes), a course of systemic corticosteroids (oral prednisolone 40-50 mg for 5-7 days), and controlled oxygen to keep saturation at 93-95%. COPD exacerbations are managed with increased bronchodilator therapy, a short prednisolone course (30-40 mg for 5 days), antibiotics when sputum becomes purulent, and the controlled 88-92% oxygen target described above. Long-term azithromycin prophylaxis and phosphodiesterase-4 inhibition with roflumilast are specialist options for frequently exacerbating COPD - know that they exist rather than their dosing detail.